Chemotherapy combination regimens for EGFR-TKI resistant metastatic EGFR-mutated NSCLC: A systematic review and network meta-analysis

被引：0
|
作者：
Qin, B. [1 ]
Jiao, X. [1 ]
Liu, K. [1 ]
Zang, Y. [1 ]
机构：
[1] Shanghai Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.697
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
664P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
    Kuiper, J. L.
    Hashemi, S. M. S.
    Thunnissen, E.
    Snijders, P. J. F.
    Grunberg, K.
    Bloemena, E.
    Sie, D.
    Postmus, P. E.
    Heideman, D. A. M.
    Smit, E. F.
    BRITISH JOURNAL OF CANCER, 2016, 115 (12) : 1504 - 1512
  • [22] Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
    J L Kuiper
    S M S Hashemi
    E Thunnissen
    P J F Snijders
    K Grünberg
    E Bloemena
    D Sie
    P E Postmus
    D A M Heideman
    E F Smit
    British Journal of Cancer, 2016, 115 : 1504 - 1512
  • [23] Upfront radiation versus EGFR-TKI: which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?
    Passiglia, Francesco
    Rolfo, Christian
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S533 - S536
  • [24] The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies
    Wang, Naiqun
    Zhang, Xiaolian
    Wang, Feilong
    Zhang, Min
    Sun, Bo
    Yin, Weihua
    Deng, Shaorong
    Wan, Ying
    Lu, Wei
    SLAS TECHNOLOGY, 2021, 26 (01): : 42 - 54
  • [25] The efficacy and safety of EGFR-TKI in recurrent/metastatic nasopharyngeal carcinoma patients: A systematic review and meta-analysis
    An, Zeqi
    He, Libin
    Chen, Tuo
    Liang, Bosen
    Wu, Qiang
    LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2024, 9 (03):
  • [26] Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
    He, Y.
    Zhao, C.
    Li, X.
    Ren, S.
    Jiang, T.
    Zhang, J.
    Su, C.
    Chen, X.
    Cai, W.
    Gao, G.
    Li, W.
    Wu, F.
    Li, J.
    Zhao, J.
    Zhou, F.
    Hu, Q.
    Hirsch, F. R.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1970 - S1970
  • [27] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis (vol 24, 1390, 2024)
    Liu, Ao
    Wang, Xiaoming
    Wang, Lian
    Zhuang, Han
    Xiong, Liubo
    Gan, Xiao
    Wang, Qian
    Tao, Guanyu
    BMC CANCER, 2025, 25 (01)
  • [28] Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis
    Mo, Zexun
    Ye, Meifeng
    He, Hua
    Huang, Xiaomei
    Guo, Weihong
    Zhao, Ziwen
    Li, Yujun
    Wei, Shuquan
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [29] Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI
    Li, W.
    Che, G.
    Zhao, J.
    Zhao, Y.
    Duan, J.
    Zhou, C.
    Zhao, X.
    Wu, L.
    Zhang, Y.
    Zhou, C.
    Zhou, C.
    Zhou, F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S105 - S106
  • [30] Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies
    Li, Li
    Huang, Qin
    Sun, Jianhai
    Yan, Fei
    Wei, Wujie
    Li, Zihui
    Liu, Li
    Deng, Jie
    ACTA ONCOLOGICA, 2022, 61 (11) : 1347 - 1353
12345